Branded Generics Market Scope And Analysis

  • Report Code : TIPRE00005554
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Branded Generics Market Analysis, Trends, and Scope 2024 to 2031

Buy Now


Branded Generics Market Report Scope

Report Attribute Details
Market size in 2023 US$ 258.85 Billion
Market Size by 2031 US$ 570.40 Billion
Global CAGR (2023 - 2031) 10.38%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Therapeutic Application
  • Oncology
  • Cardiovascular Diseases
  • Diabetes
  • Neurology
  • Gastrointestinal Diseases
  • Dermatology Diseases
  • Analgesics & Anti-Inflammatory
By Drug Class
  • Alkylating Agents
  • Antimetabolites
  • Hormones
  • Antihypertensive
  • Lipid-Lowering Drugs
  • Antidepressants
  • Antipsychotics
  • Antiepileptic
By Formulation Type
  • Oral
  • Parenteral
  • Topical
By Distribution Channel
  • Hospitals
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Hetero
  • Aspen Holdings
  • Sandoz International GMBH
  • Par Pharmaceuticals INC
  • Dr Reddy s Laboratories
  • AstraZeneca PLC
  • Sanofi
  • Lupin
  • Bausch Health Companies Inc
  • GlaxoSmithKline plc
  • Branded Generics Market News and Recent Developments

    The Branded Generics market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes essential corporate publications, association data, and databases. A few of the developments in the Branded Generics market are listed below:

    • Novartis’Sandoz launched a generic version of AbbVie’s Combigan, a combo eye drop used to treat elevated eye pressure in the U.S. As the most-dispensed branded combo glaucoma medication, the originator reeled in $373 million in U.S. sales in 2021. With the launch, the company is expanding its eye drug offerings.  (Source: Sandoz, Company Website, April 2022)
    • GSK agreed to acquire Sierra Oncology, a California-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, for US$ 55 per share of common stock in cash, representing an approximate total equity value of US$ 1.9 billion (£1.5 billion). (Source: GlaxoSmithKline plc., Press Release, April 2022)

    Branded Generics Market Report Coverage and Deliverables

    The “Branded Generics Market Size and Forecast (2021–2031)” report provides a comprehensive breakdown of the market covering the areas:

    • Branded Generics market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Branded Generics market trends, as well as market dynamics such as drivers, restraints, and key opportunities
    • Detailed PEST/Porter’s Five Forces and SWOT analysis
    • Branded Generics market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Branded Generics market
    • Detailed company profiles